How to Foster Communication Among all Members of the Cancer Care Team with Pathologists to Deliver Individualized Treatment for Patients with Lung Cancer

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Drs Roy Herbst and David Rimm consider novel ways that surgeons, interventional radiologists, pulmonologists, medical oncologists, and pathologists interact at Yale Cancer Center to maximize the use of common molecular biomarkers, as well as NGS and TMB, in providing precision medicine to lung cancer patients.

Related Videos

October 16, 2015

Targeting Multiple Pathways with Immunotherapies

Dr. Sanjiv Agarwala brings up the potential issue of toxicity that may arise in combining immunotherapies and argues that the benefits outweigh the risks.

July 13, 2021

NTRK Gene Fusion Enrichment in Patient Subpopulations

Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, identify specific subpopulations of patients in which NTRK gene fusions may be commonly uncovered.